Lundbeck announces changes to Executive Management

Valby, Denmark, February 23, 2024 - H. Lundbeck A/S (Lundbeck) today announced the following changes in the Executive Management team.

Jacob Tolstrup, Executive Vice President, Commercial Operations will leave Lundbeck no later than March 1, 2024.

Jacob Tolstrup joined Lundbeck in 1999 and has held various management positions across the company, becoming a member of Lundbeck's Executive Management team in 2012.

"We would like to express gratitude to Jacob for his long-standing commitment to Lundbeck. Jacob has been a valuable member of Lundbeck's leadership team, leveraging his extensive experience to make a significant impact. We wish Jacob all the best in his future endeavours," says Charl van Zyl, President and CEO of Lundbeck.

As part of the changes within the Executive Management team, Lundbeck is pleased to announce that Michala Fischer-Hansen will join the company in a new role as Head of Europe and International Markets and a member of Lundbeck's Executive Management team, assuming the role no later than April 8, 2024.

Michala Fischer-Hansen is a seasoned executive leader, who brings a wealth of international experience, particularly within the biopharmaceutical sector. Michala has a strong track record in improving business performance and has been part of the executive management team at Falck since 2019 following a 19-year commercial career at Novo Nordisk.

"We are delighted to welcome Michala Fischer-Hansen to Lundbeck. Michala brings a rich background in achieving significant outcomes, demonstrating an ability to lead through business transformations, and will greatly contribute to ensuring Lundbeck's sustained long-term value creation as a focused innovator," says Charl van Zyl, President and CEO of Lundbeck.

Furthermore, Keld Flintholm Jørgensen, who currently serves as Executive Vice President and Head of Corporate Business Development and Strategy, will continue in a role exclusively focused on Corporate Business Development, transitioning from the Executive Management team to becoming Senior Vice President and Head of Corporate Business Development, reporting to Lundbeck's President and CEO, Charl van Zyl.

Finally, Lundbeck has initiated a comprehensive search to identify the right candidate to take on a newly established role in the company as Executive Vice President, Head of Commercial and Corporate Strategy, and a member of Lundbeck's Executive Management team. The creation of the new position aims to strengthen corporate strategic functions and global marketing to enhance Lundbeck's ability to capitalize on present and future opportunities.
 

• Charl van Zyl, President & CEO
• Lars Bang, Executive Vice President, Product Development & Supply
• Thomas Gibbs, Executive Vice President, Head of U.S.
• Michala Fischer-Hansen, Executive Vice President, Head of Europe & International Markets
• Tine Østergaard Hansen, Senior Vice President, Head of Corporate Communication and Public Affairs[1]
• Dianne Hol, Executive Vice President, Head of People & Organization
• Joerg Hornstein, Executive Vice President, Chief Financial Officer
• Johan Luthman, Executive Vice President, Head of R&D
• Vacant, Executive Vice President, Head of Commercial & Corporate Strategy

Lundbeck contacts

Investors:                                    Media:
Palle Holm Olesen Thomas Mikkel
Mortensen
Vice President, Investor Relations Media Relations Lead,
Corporate
Communication
PALO@lundbeck.com THMR@lundbeck.com
+45 30 83 24 26 +45 30 83 30 24

Sophia Nørskov Bech
Senior Manager, Investor Relations
SONQ@lundbeck.com
+45 30 83 24 60

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases. As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options. Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

Safe Harbor/Forward-Looking Statements

This corporate release contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements.

Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

The forward-looking statements in this document and oral presentations made on behalf of Lundbeck speak only as at the date of this presentation. Lundbeck does not undertake any obligation to update or revise forward-looking statements in this presentation or oral presentations made on behalf of Lundbeck, nor to confirm such statements to reflect subsequent events or circumstances after the date of the presentation or in relation to actual results, unless otherwise required by applicable law or applicable stock exchange regulations.
 

[1] Not formally a member of Executive Management but participates in all meetings.